Sunday, February 24, 2013

VentriPoint Announces 3D Ultrasound Heart Analysis System and Prepares for Clinical Release

SEATTLE, WASHINGTON, Feb 21, 2013 (MARKETWIRE via COMTEX) -- VentriPoint Diagnostics CA:VPT +10.00% (otcqx:VPTDF) is pleased to announce the completion of a software package for 3D Echocardiography (3DE) - the newest addition to the software capabilities of its knowledge-based-reconstruction (KBR) family of VMS(TM) heart analysis systems. The VMS-3DE(TM) product works with all existing KBR databases and so can be applied to Tetralogy of Fallot (TOF), dextro-Transposition of the Great Arteries (d-TGA), Pulmonary Arterial Hypertension (PAH) and most right ventricles (NRV) without congenital heart disease or PAH including normal hearts.

"The VMS-3DE(TM) heart analysis system addresses a direct need in the ultrasound community by providing fast and accurate analyses of 3D acquired images of the right ventricle, which, up until now, has presented a significant challenge," stated Dr. George Adams, CEO of VentriPoint. "3D echocardiographic imaging has continued to improve and for more and more patients (usually children) clinically-useful images can now be obtained. But there has been a void in available tools to accurately analyze the right ventricle. Our new product fills this void and positions Ventripoint as a leader in this emerging segment of the market".

Initial clinical evaluation of the VMS-3DE(TM) product was performed at the Heart and Diabetes Center North Rhine-Westphalia, Bad Oeynhausen, Germany.

source: Marketwire

No comments: